Genetic Risk of Alzheimer’s Disease: Three Wishes Now That the Genie is Out of the Bottle

Manuscript Number: 

18-0629R2

Author(s): 
J. Wesson Ashford, Peter J. Bayley, Soo Borson, Herman Buschke, Donna Cohen, Jeffrey Cummings, Peter Davies, Margaret Dean, Sanford I. Finkel, Lori Frank, Lee Hyer, George Perry, Richard E. Powers, Frederick A. Schmitt

Disclosures

J. Wesson Ashford

  • Nothing to Disclose

Peter J. Bayley

  • Nothing to Disclose

Soo Borson

  • Nothing to Disclose

Herman Buschke

  • Nothing to Disclose

Donna Cohen

  • Nothing to Disclose

Jeffrey Cummings

  • Consulting Fees:
    Personal payment for advisory board; input is for trial design and interpretation; fees are commensurate with market rate
    Equity:
    Stock options: BiOasis, MedAvante Stock: ADAMAS

Peter Davies

  • Nothing to Disclose

Margaret Dean

  • Nothing to Disclose

Sanford I. Finkel

  • Nothing to Disclose

Lori Frank

  • Nothing to Disclose

Lee Hyer

  • Nothing to Disclose

George Perry

  • Consulting Fees:
    Neurotez Neurotrope Phoenix Biotech Investicure
    Equity:
    Neurotrope Neurotez
    Grants
    • Agency: 
      Phoenix Biotech

Richard E. Powers

  • Nothing to Disclose

Frederick A. Schmitt

  • Nothing to Disclose